University Hospital Birmingham NHS Foundation Trust Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2013
NCT01668459
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Birmingham Women's and Children's Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

cabazitaxel (jevtana kit) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1